/AXNX

AXNX Stock - Axonics, Inc.

Q: What is the analyst price target for AXNX?

Analyst price target information is not currently available for AXNX.

Q: What is AXNX's market cap?

Market capitalization information is not currently available for AXNX.

Healthcare|Medical - Devices|NASDAQ

$70.98+0.00%

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+0.0%upside

Target: $70.98

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for AXNX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.83

52W High$70.98

52W Low$70.98

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	$366.38M	$273.70M	$180.29M	$111.53M	$13.82M
Gross Profit	$274.55M	$197.66M	$115.72M	$67.09M	$7.33M
Gross Margin	74.9%	72.2%	64.2%	60.2%	53.0%
Operating Income	$-26,057,000	$-42,385,000	$-67,394,000	$-53,760,000	$-80,599,000
Net Income	$-6,088,000	$-59,698,000	$-80,067,000	$-54,915,000	$-79,935,000
Net Margin	-1.7%	-21.8%	-44.4%	-49.2%	-578.4%
EPS	$-0.12	$-1.28	$-1.86	$-1.48	$-2.80

Company Overview

Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

75%

Hold / Neutral

25%

Sell / Underperform

Analyst Consensus🟢 Bullish

6 Bullish2 Neutral/Bearish

Price Targets

$74

Average Target

↑ 3.7% Upside

Now

$69

Low

$74

Average

$85

High

Based on 8 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
January 9th 2024	Wolfe Research	Downgrade	Peer Perform	-
July 19th 2023	Robert W. Baird	Initiation	Outperform	$69
July 13th 2023	KeyBanc Capital Markets	Initiation	Overweight	$70
May 23rd 2023	CL King	Initiation	Buy	$75
April 14th 2023	Mizuho	Initiation	Buy	$75
March 24th 2023	Needham	Upgrade	Buy	$71
October 21st 2022	RBC Capital Mkts	Initiation	Outperform	$85
October 12th 2022	Jefferies	Initiation	Hold	$75
October 10th 2022	Needham	Downgrade	Hold	-
April 6th 2022	Wolfe Research	Initiation	Outperform	$69

Earnings History & Surprises

AXNX

Beat Rate

70%

Last 20 quarters

Avg Surprise

+0.4%

EPS vs Estimate

Beats / Misses

14/5

1 met exactly

Latest EPS

$0.16

Q4 2024

EPS Surprise History

Q1 23

+104.2%

$0.01vs$-0.24

Q2 23

+44.1%

$-0.19vs$-0.34

Q3 23

-25.0%

$-0.15vs$-0.12

Q4 23

+260.0%

$0.08vs$-0.05

Q1 24

+116.7%

$0.13vs$0.06

Q2 24

-660.0%

$-0.38vs$-0.05

Q3 24

0.0%

$0.13vs$0.13

Q4 24

+23.1%

$0.16vs$0.13

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2024	Nov 7, 2024	$0.13	$0.16	+23.1%	✓ BEAT
Q3 2024	Aug 1, 2024	$0.13	$0.13	0.0%	= MET
Q2 2024	Apr 30, 2024	$-0.05	$-0.38	-660.0%	✗ MISS
Q1 2024	Feb 28, 2024	$0.06	$0.13	+116.7%	✓ BEAT
Q4 2023	Oct 30, 2023	$-0.05	$0.08	+260.0%	✓ BEAT
Q3 2023	Jul 27, 2023	$-0.12	$-0.15	-25.0%	✗ MISS
Q2 2023	May 1, 2023	$-0.34	$-0.19	+44.1%	✓ BEAT
Q1 2023	Mar 1, 2023	$-0.24	$0.01	+104.2%	✓ BEAT
Q4 2022	Oct 31, 2022	$-0.47	$-0.34	+27.7%	✓ BEAT
Q3 2022	Aug 1, 2022	$-0.57	$-0.47	+17.5%	✓ BEAT
Q2 2022	May 5, 2022	$-0.69	$-0.50	+27.5%	✓ BEAT
Q1 2022	Feb 24, 2022	$-0.36	$-0.34	+5.6%	✓ BEAT
Q4 2021	Nov 4, 2021	$-0.46	$-0.38	+17.4%	✓ BEAT
Q3 2021	Aug 5, 2021	$-0.51	$-0.59	-15.7%	✗ MISS
Q2 2021	May 6, 2021	$-0.41	$-0.46	-12.2%	✗ MISS
Q1 2021	Feb 25, 2021	$-0.32	$-0.29	+9.4%	✓ BEAT
Q4 2020	Nov 4, 2020	$-0.52	$-0.24	+53.8%	✓ BEAT
Q3 2020	Aug 6, 2020	$-0.59	$-0.54	+8.5%	✓ BEAT
Q2 2020	May 5, 2020	$-0.56	$-0.43	+23.2%	✓ BEAT
Q1 2020	Mar 4, 2020	$-0.64	$-0.75	-17.2%	✗ MISS